TWI822754B - 作為crhr2拮抗劑之稠合環狀脲衍生物 - Google Patents

作為crhr2拮抗劑之稠合環狀脲衍生物 Download PDF

Info

Publication number
TWI822754B
TWI822754B TW108112345A TW108112345A TWI822754B TW I822754 B TWI822754 B TW I822754B TW 108112345 A TW108112345 A TW 108112345A TW 108112345 A TW108112345 A TW 108112345A TW I822754 B TWI822754 B TW I822754B
Authority
TW
Taiwan
Prior art keywords
methyl
oxo
chloro
cyclohexyl
dihydro
Prior art date
Application number
TW108112345A
Other languages
English (en)
Chinese (zh)
Other versions
TW201945355A (zh
Inventor
大見仁
松下岳史
安藤一男
山口龍一
福元豊
真柄良平
山岸竜也
竹藤幹人
Original Assignee
日商拉夸里亞創藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商拉夸里亞創藥股份有限公司 filed Critical 日商拉夸里亞創藥股份有限公司
Publication of TW201945355A publication Critical patent/TW201945355A/zh
Application granted granted Critical
Publication of TWI822754B publication Critical patent/TWI822754B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Ink Jet (AREA)
TW108112345A 2018-04-09 2019-04-09 作為crhr2拮抗劑之稠合環狀脲衍生物 TWI822754B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862654628P 2018-04-09 2018-04-09
US62/654,628 2018-04-09

Publications (2)

Publication Number Publication Date
TW201945355A TW201945355A (zh) 2019-12-01
TWI822754B true TWI822754B (zh) 2023-11-21

Family

ID=68164246

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108112345A TWI822754B (zh) 2018-04-09 2019-04-09 作為crhr2拮抗劑之稠合環狀脲衍生物

Country Status (11)

Country Link
US (1) US11802120B2 (cg-RX-API-DMAC10.html)
EP (1) EP3774739B1 (cg-RX-API-DMAC10.html)
JP (1) JP7357932B2 (cg-RX-API-DMAC10.html)
KR (1) KR102590854B1 (cg-RX-API-DMAC10.html)
CN (1) CN111868037B (cg-RX-API-DMAC10.html)
BR (1) BR112020020708A8 (cg-RX-API-DMAC10.html)
CA (1) CA3094609A1 (cg-RX-API-DMAC10.html)
ES (1) ES2917634T3 (cg-RX-API-DMAC10.html)
MX (1) MX2020010568A (cg-RX-API-DMAC10.html)
TW (1) TWI822754B (cg-RX-API-DMAC10.html)
WO (1) WO2019198692A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122023023802A2 (pt) 2015-04-29 2023-12-26 Janssen Pharmaceutica Nv Compostos azabenzimidazóis, seu uso como moduladores do receptor de ampa e composições farmacêuticas que os compreendem
WO2021145401A1 (en) * 2020-01-15 2021-07-22 Raqualia Pharma Inc. Spiroheterocyclic derivatives as crhr2 antagonist
EP3901152A1 (en) * 2020-04-23 2021-10-27 F. Hoffmann-La Roche AG Kv3 enhancers for the treatment of cognitive disorders
CR20220565A (es) * 2020-05-06 2023-01-13 Merck Sharp & Dohme Llc Inhibidores de il4i1 y métodos de uso
WO2022071484A1 (en) * 2020-09-30 2022-04-07 Raqualia Pharma Inc. 3-hydroxyoxindole derivatives as crhr2 antagonist
WO2022228365A1 (zh) * 2021-04-27 2022-11-03 南京明德新药研发有限公司 六元杂芳并脲环的衍生物及其应用
KR20250113346A (ko) * 2024-01-17 2025-07-25 주식회사 엘지화학 CBP/p300 저해제로 사용되는 신규 화합물, 및 이를 유효성분으로 포함하는 암, 염증성 장애 또는 자가면역 질환의 예방 또는 치료용 약학 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015655A1 (en) * 2008-08-07 2010-02-11 Novartis Ag Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists
WO2011092293A2 (en) * 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
WO2011095450A1 (en) * 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
WO2013160317A2 (en) * 2012-04-23 2013-10-31 Holsboermaschmeyer Neurochemie Gmbh Crhr1 antagonists for use in the treatment of patients having crh overactivity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3538899A (en) * 1998-04-30 1999-11-23 Nippon Chemiphar Co. Ltd. Condensed imidazole derivative and therapeutic agent for liver disease
CA2446514A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
ATE397609T1 (de) * 2001-06-12 2008-06-15 Glaxo Group Ltd Corticotropinfreisetzungsfaktor antagonisten
JP2007161585A (ja) * 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
US7652035B2 (en) 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
US10166271B2 (en) 2006-06-21 2019-01-01 The Regents Of The University Of California Methods for promoting hair growth

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015655A1 (en) * 2008-08-07 2010-02-11 Novartis Ag Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists
WO2011092293A2 (en) * 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
WO2011095450A1 (en) * 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
WO2013160317A2 (en) * 2012-04-23 2013-10-31 Holsboermaschmeyer Neurochemie Gmbh Crhr1 antagonists for use in the treatment of patients having crh overactivity

Also Published As

Publication number Publication date
MX2020010568A (es) 2020-10-22
TW201945355A (zh) 2019-12-01
CN111868037B (zh) 2023-10-13
ES2917634T3 (es) 2022-07-11
BR112020020708A8 (pt) 2022-10-18
EP3774739A1 (en) 2021-02-17
JP7357932B2 (ja) 2023-10-10
US20210078975A1 (en) 2021-03-18
BR112020020708A2 (pt) 2021-01-12
WO2019198692A1 (en) 2019-10-17
US11802120B2 (en) 2023-10-31
CN111868037A (zh) 2020-10-30
KR102590854B1 (ko) 2023-10-18
EP3774739A4 (en) 2021-08-25
CA3094609A1 (en) 2019-10-17
JP2021521142A (ja) 2021-08-26
EP3774739B1 (en) 2022-05-11
KR20200135834A (ko) 2020-12-03

Similar Documents

Publication Publication Date Title
US12503439B2 (en) Heteroaryl compounds for the treatment of pain
US9051296B2 (en) Aryl carboxamide derivatives as TTX-S blockers
KR102590854B1 (ko) Crhr2 길항제로서의 축합 환상 요소 유도체
KR102425400B1 (ko) Trpm8 길항제로 사용되는 아자스피로 유도체
JP2026506002A (ja) Sos1阻害剤及び抗がん薬を含む、がんの処置のための医薬組成物
CN110214136A (zh) 作为malt1抑制剂的吡唑衍生物
JP2018521025A (ja) Tnf活性のモジュレーターとしてのベンゾオキサジノン誘導体およびその類似体
KR20150013180A (ko) Ttx-s 차단제로서 아미드 유도체
CN105814054A (zh) 作为tnf活性调节剂的稠合咪唑和吡唑衍生物
TWI601726B (zh) 吡唑並吡啶衍生物作爲ttx-s阻斷劑
TW202140480A (zh) 作為crhr2拮抗劑之螺雜環衍生物
KR20230005227A (ko) Trpv4 길항제로서의 피리미딘-4(3h)-온 유도체
IL325136A (en) Pyrazolo-pyrimidinone compounds for use in methods for inhibiting kinase week1 a
US12421191B2 (en) 3-hydroxyoxindole derivatives as CRHR2 antagonist
TW202400612A (zh) 作為HPK1抑制劑之四氫吡啶并[3,4-d]嘧啶化物
RU2778641C2 (ru) Производные конденсированной циклической мочевины в антагонист crhr2
HK40037565A (en) Fused cyclic urea derivatives as crhr2 antagonist
HK40043109A (en) Fused cyclic urea derivatives as crhr2 antagonist
HK40043109B (en) Fused cyclic urea derivatives as crhr2 antagonist
HK40078094A (en) Pyrimidin-4(3h)-one derivatives as trpv4 antagonists